Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Name
Felix Boakye-Agyeman MD PhD
Title
VP, Consulting, Certara
Bio
Dr. Felix Boakye-Agyeman is Vice President of Pharmacometrics within the Integrated Drug Development (IDD) group at Certara, a global leader in model-informed drug development. Certara partners with more than 2,300 organizations worldwide and has contributed over 99% of all new drug approvals in the past decade.
At Certara, Dr. Boakye-Agyeman leads a multidisciplinary team of scientists who integrate quantitative modeling and clinical pharmacology, and to optimize drug development across therapeutic areas. His work has directly supported the development and approval of multiple therapies, particularly in oncology, immunology, and pediatric indications.
With a background spanning medicine, clinical pharmacology, and quantitative sciences, Dr. Boakye-Agyeman is recognized for advancing model-informed strategies for special and vulnerable populations, ensuring that data-driven innovation translates into safer and more effective therapies.
Prior to joining Certara, he held leadership roles at Synteract, where he oversaw pharmacometric consulting for adult and pediatric programs, and at the Duke Clinical Research Institute (DCRI), supporting early-phase and pediatric trials through the NIH-funded Pediatric Trials Network. His contributions have informed pediatric dosing strategies and labeling updates by major regulatory agencies, including the FDA, EMA, PMDA, NMPA, and Health Canada.
Beyond his role at Certara, Dr. Boakye-Agyeman serves on the Board of Africa Partners Medical (APM), where for over 15 years he has contributed to health system strengthening, medical training, and quality improvement initiatives across Ghana and West Africa.
Functional Expertise
• Population PK
• Exposure Response Analysis
• PK/PD analysis
• Non-compartmental analysis
• Concentration QTc analysis
• Clinical pharmacology
Specialty Areas
• Oncology
• Autoimmune
• Infectious diseases
• Antibody drug conjugates (ADC)
• Special Populations (Pediatrics, Maternal Health)
At Certara, Dr. Boakye-Agyeman leads a multidisciplinary team of scientists who integrate quantitative modeling and clinical pharmacology, and to optimize drug development across therapeutic areas. His work has directly supported the development and approval of multiple therapies, particularly in oncology, immunology, and pediatric indications.
With a background spanning medicine, clinical pharmacology, and quantitative sciences, Dr. Boakye-Agyeman is recognized for advancing model-informed strategies for special and vulnerable populations, ensuring that data-driven innovation translates into safer and more effective therapies.
Prior to joining Certara, he held leadership roles at Synteract, where he oversaw pharmacometric consulting for adult and pediatric programs, and at the Duke Clinical Research Institute (DCRI), supporting early-phase and pediatric trials through the NIH-funded Pediatric Trials Network. His contributions have informed pediatric dosing strategies and labeling updates by major regulatory agencies, including the FDA, EMA, PMDA, NMPA, and Health Canada.
Beyond his role at Certara, Dr. Boakye-Agyeman serves on the Board of Africa Partners Medical (APM), where for over 15 years he has contributed to health system strengthening, medical training, and quality improvement initiatives across Ghana and West Africa.
Functional Expertise
• Population PK
• Exposure Response Analysis
• PK/PD analysis
• Non-compartmental analysis
• Concentration QTc analysis
• Clinical pharmacology
Specialty Areas
• Oncology
• Autoimmune
• Infectious diseases
• Antibody drug conjugates (ADC)
• Special Populations (Pediatrics, Maternal Health)
